Encouraging results from a phase III placebo-controlled trial suggest that glatiramer acetate (already licensed for relapsing-remitting multiple sclerosis) is effective in reducing progression to clinically definite disease after a first clinically isolated syndrome. Individuals were studied for three years, with MRI analysis done every 3 months to compare underlying disease progression with clinical symptoms. The study is discussed in a podcast.
Market Data 
Markets 
AI
